Cargando…
Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay
OBJECTIVE: This study aimed to clarify the clinical features, the serum level of autoantibodies, and cytokine of myositis patients with anti-EJ antibody, which targets glycyl tRNA-synthetase (GlyRS). METHODS: Sera of 236 Chinese patients with myositis were screened for anti-EJ by a novel immunopreci...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452540/ https://www.ncbi.nlm.nih.gov/pubmed/31019965 http://dx.doi.org/10.1155/2019/1856180 |
_version_ | 1783409310069424128 |
---|---|
author | Yang, Yang Liu, Yangtengyu Huang, Li Wang, Li Liu, Ke Liu, Meidong Luo, Hui Zuo, Xiaoxia Li, Yisha Zhang, Huali |
author_facet | Yang, Yang Liu, Yangtengyu Huang, Li Wang, Li Liu, Ke Liu, Meidong Luo, Hui Zuo, Xiaoxia Li, Yisha Zhang, Huali |
author_sort | Yang, Yang |
collection | PubMed |
description | OBJECTIVE: This study aimed to clarify the clinical features, the serum level of autoantibodies, and cytokine of myositis patients with anti-EJ antibody, which targets glycyl tRNA-synthetase (GlyRS). METHODS: Sera of 236 Chinese patients with myositis were screened for anti-EJ by a novel immunoprecipitation assay of flag-tagged GlyRS. Anti-EJ positive patients are evaluated for the clinical features and cytokine profile. RESULTS: The sera from 4 of 236 adult myositis patients were found to carry the anti-EJ using established novel immunoprecipitation assay and immunoblotting. The prevalence of anti-EJ in our cohorts is about 1.7%. The decline of anti-EJ level was detected in two patients during disease remission. Interstitial lung disease and muscle weakness, but not skin involvement, are common clinical features of anti-EJ positive patients. Moreover, using a cytokine profile analyses, we found that the serum levels of IP-10, IL-6, MCP-1, and VEGF were significantly elevated in patients with anti-EJ and gradually decreased during disease remission of two patients, whereas IL-8 level was obviously reduced in these patients. CONCLUSION: The novel immunoprecipitation assay is suitable to detect and monitor the levels of anti-EJ autoantibody. The serum levels of anti-EJ, IP-10, IL-6, MCP-1, and VEGF may be related to disease activity in myositis patients with anti-EJ antibodies. |
format | Online Article Text |
id | pubmed-6452540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-64525402019-04-24 Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay Yang, Yang Liu, Yangtengyu Huang, Li Wang, Li Liu, Ke Liu, Meidong Luo, Hui Zuo, Xiaoxia Li, Yisha Zhang, Huali Biomed Res Int Research Article OBJECTIVE: This study aimed to clarify the clinical features, the serum level of autoantibodies, and cytokine of myositis patients with anti-EJ antibody, which targets glycyl tRNA-synthetase (GlyRS). METHODS: Sera of 236 Chinese patients with myositis were screened for anti-EJ by a novel immunoprecipitation assay of flag-tagged GlyRS. Anti-EJ positive patients are evaluated for the clinical features and cytokine profile. RESULTS: The sera from 4 of 236 adult myositis patients were found to carry the anti-EJ using established novel immunoprecipitation assay and immunoblotting. The prevalence of anti-EJ in our cohorts is about 1.7%. The decline of anti-EJ level was detected in two patients during disease remission. Interstitial lung disease and muscle weakness, but not skin involvement, are common clinical features of anti-EJ positive patients. Moreover, using a cytokine profile analyses, we found that the serum levels of IP-10, IL-6, MCP-1, and VEGF were significantly elevated in patients with anti-EJ and gradually decreased during disease remission of two patients, whereas IL-8 level was obviously reduced in these patients. CONCLUSION: The novel immunoprecipitation assay is suitable to detect and monitor the levels of anti-EJ autoantibody. The serum levels of anti-EJ, IP-10, IL-6, MCP-1, and VEGF may be related to disease activity in myositis patients with anti-EJ antibodies. Hindawi 2019-03-25 /pmc/articles/PMC6452540/ /pubmed/31019965 http://dx.doi.org/10.1155/2019/1856180 Text en Copyright © 2019 Yang Yang et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Yang, Yang Liu, Yangtengyu Huang, Li Wang, Li Liu, Ke Liu, Meidong Luo, Hui Zuo, Xiaoxia Li, Yisha Zhang, Huali Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay |
title | Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay |
title_full | Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay |
title_fullStr | Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay |
title_full_unstemmed | Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay |
title_short | Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay |
title_sort | clinical features and cytokine profile in myositis patients with anti-ej autoantibodies detected by a novel immunoprecipitation assay |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452540/ https://www.ncbi.nlm.nih.gov/pubmed/31019965 http://dx.doi.org/10.1155/2019/1856180 |
work_keys_str_mv | AT yangyang clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay AT liuyangtengyu clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay AT huangli clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay AT wangli clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay AT liuke clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay AT liumeidong clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay AT luohui clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay AT zuoxiaoxia clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay AT liyisha clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay AT zhanghuali clinicalfeaturesandcytokineprofileinmyositispatientswithantiejautoantibodiesdetectedbyanovelimmunoprecipitationassay |